Want to cut your energy bills? Here’s how five experts are doing it 
NVIDIA Acquisition Rumors Dismissed by Morgan Stanley as Strategically Flawed 
JAPEX Shares Drop as Middle East Tensions Drive LNG Costs and Production Risks 
SpaceX Eyes $60B Cursor Deal to Boost AI Power Ahead of IPO 
Indonesia and Toyota Explore $300M Bioethanol Investment to Boost Renewable Energy Goals 
Polymarket Seeks $400M Funding Round, Targets $15B Valuation Amid Prediction Market Boom 
Amazon Expands AI Bet with Up to $25 Billion Investment in Anthropic 
Eli Lilly in Talks to Acquire Kelonia Therapeutics for Over $2 Billion 
Nvidia Pushes 800V Data Center Power Systems to Boost Efficiency and Cut Costs 
Indian Refiners Use Yuan via ICICI Bank to Pay for Iranian Oil Under U.S. Sanctions Waiver 
John Ternus Signals Apple’s Future with Product-First AI Strategy 
J.P. Morgan Downgrades Essity AB on Rising Costs and Weak Earnings Outlook 
Samsung Boosts DRAM Supply to Tesla as AI-Driven Memory Demand Surges 
SK Hynix to Invest $13 Billion in AI Chip Packaging Facility 
Apple Stock Dips as Tim Cook Steps Down, John Ternus Named Next CEO 
OPmobility Reports Q1 Revenue Dip Amid Automotive Industry Slowdown 
Ethiopian Airlines Expands Fleet with New Boeing 787 Dreamliner Order to Boost Global Routes 
 and Lead Plaintiff Deadline - July 17, 2017 - EconoTimes)
NEW YORK, May 25, 2017 -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Neurotrope, Inc. (“Neurotrope” or the “Company”) (NASDAQ:NTRP) and certain of its officers, on behalf of shareholders who purchased Neurotrope securities between January 7, 2016, and April 28, 2017, both dates inclusive (the “Class Period”). Such investors are encouraged to join this case by visiting the firm’s site: http://www.bgandg.com/ntrp.
This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934.
The Complaint alleges that throughout the Class Period, Defendants made materially false and misleading statements and/or failed to disclose material adverse information regarding the efficacy of its lead product candidate, Bryostatin-1.
On May 1, 2017, Neurotrope announced “positive top-line results” of the focal Phase 2b trials of Bryostatin-1, mentioning “improvement in patients with moderate to severe Alzheimer’s disease.” Conversely, the trial data allegedly negates these statements, as the top-line data relating to the 20 microgram dose of Bryostatin-1 did not produce statistically significant results. Neurotrope also allegedly failed to disclose statements about the efficacy of the 40 microgram dose in connection with its primary and secondary endpoints. Following this news, Neurotrope stock dropped from a close of $18.81 per share on April 28, 2017, to a close at $6.97 per share on May 1, 2017.
A class action lawsuit has already been filed. If you wish to review a copy of the Complaint you can visit the firm’s site: http://www.bgandg.com/ntrp or you may contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484. If you suffered a loss in Neurotrope you have until July 17, 2017 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.
Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm’s expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.
Contact: Bronstein, Gewirtz & Grossman, LLC Peretz Bronstein or Yael Hurwitz 212-697-6484 | [email protected]
